In the October 2018 issue of International Journal of Clinical Oncology, in the article titled “Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)” (volume 23, pages 965–973; doi: https ://doi.org/10.1007/s1014 7-018-1281-8.), by Hishiki T et al., there was a printing error in Figure 1. In the description for the schedule of the induction regime 05A1 and 05A3, the arrow that shows the day of pirarubicin administration was intended to indicate day 3, but in error had been published with the arrows indicating purarubicin administration on day 2. We sincerely apologize for this error in the schedule of the regime.
All Science Journal Classification (ASJC) codes